Journal
METABOLIC BRAIN DISEASE
Volume 37, Issue 2, Pages 451-462Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-021-00879-1
Keywords
Parkinson's disease; Liraglutide; AMPK; NF-kappa B; Neuroinflammation
Categories
Funding
- Science Foundation of Hebei Normal University [L2020Z05]
- Hebei Province Foundation for Returnees [C20200341]
Ask authors/readers for more resources
Parkinson's disease (PD) is associated with inflammation, and GLP-1 plays a crucial role in neuroinflammation inhibition. Liraglutide suppresses neuroinflammation through the AMPK/NF-κB signaling pathway.
Parkinson's disease (PD) is a neurodegenerative disease with increasing incidence in aged populations, second only to Alzheimer's disease. Increasing evidence has shown that inflammation plays an important role in the occurrence and development of Parkinson's disease. Growing evidence has shown that AMP-activated protein kinase (AMPK) and NF-kappa B are closely related to inflammation. Glucagon-like peptide 1 (GLP-1) is a hormone that is primarily secreted by intestinal endocrine L cells, and it has a variety of physiology through binding to GLP-1 receptor. GLP-lcan be used for treatment of type 2 diabetes. In addition, GLP-1 also has anti-neuroinflammation activity. However, the exact mechanism behind how GLP-1 regulates neuroinflammation remains unclear. This study was designed to examine the effect of liraglutide on 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced injury in mice and its potential mechanism of action. Results showed that liraglutide dose-dependently ameliorated mouse behavior including swimming time and locomotor activity, increased the number of tyrosine hydroxylase (TH)-positive neurons and protein level, and reduced Ibal and GFAP expression in the substantia nigra (SN). Liraglutide treatment also increased p-AMPK expression and reduced NF-kappa B protein level. Applying the AMPK inhibitor Dorsomorphin (Compound C) reversed the effect of liraglutide-reducing p-AMPK and increasing NF-kappa B expression. Finally, GFAP protein level increased, along with a decrease in TH expression. In conclusion, these results suggest that liraglutide can suppress neuroinflammation. Moreover, this effect is mediated through the AMPK/NF-kappa B signaling pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available